News & Topics
News&Topics

2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2011.12.26
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
2011.12.13
Onconova Presents Phase Ⅰ Data for Oral Rigosertib at the 53rd American Society of Hematology Annual Meeting
2011.11.14
Clinical Trial Notification Accepted for SymBio's Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
2011.11.11
Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2011
2011.11.10
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Frontline Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
2011.10.25
Results of Third Party Allocation of New Shares
2011.10.21
SymBio Announces Taiwan NDA Approval of Bendamustine Hydrochloride(SyB L-0501)
2011.10.20
SymBio Pharmaceuticals Limited was listed on Osaka Securities Exchange JASDAQ Growth Market
2011.10.20
Financial Disclosure for SymBio’s New Listing on Osaka Securities Exchange JASDAQ Growth Market
2011.10.19
Homepage renewal
2011.10.11
Determination of Issuance Price Per Share, Equity Offering Price and Number of Shares by Overallotment
2011.09.29
Amount to Be Paid for New Shares and Tentative Terms for Book Building
2011.09.14
Corporate Resolution for SymBio’s Initial Public Offering of Shares on JASDAQ
2011.08.26
BioCentury article on Rigosertib deal between SymBio and Onconova
2011.07.11
Onconova and SymBio Complete License Agreement for Rigosertib, a Phase Ⅲ Stage Multi-Kinase Inhibitor for Cancer
2011.06.03
SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501)
2011.05.11
The news of Human Resources
2011.02.25
SymBio Pharmaceuticals Successfully Completes JPY2.0 Billion (USD24 Million) Series E Private Placement